• Is the Webjet share price a cheap buy today?

    plane flying across share markey graph, asx 200 travel shares, qantas share price

    The Webjet Limited (ASX: WEB) share price rocketed 8.45% last week and has opened higher today. But will the Aussie travel share continue to head higher in 2020?

    Is the Webjet share price a cheap buy?

    It was a good week for the S&P/ASX 200 Index (ASX: XJO) which climbed 4.22% higher to 5,998.70 points.

    Webjet was just one of many ASX 200 shares to climb higher as investors piled into shares. 

    There’s growing optimism about ASX travel shares like Webjet as coronavirus restrictions continue to ease. 

    It looks like there will still be some tough times ahead. However, many Aussies have been cooped up and are looking towards their next getaway.

    Whether that is domestically or overseas, it’s good news for the Webjet share price. The ASX travel share is still down nearly 50% in 2020 which is a healthy discount. In contrast, the S&P/ASX 200 Index has fallen just 7.67% lower at the time of writing.

    That could mean the Webjet share price is a bargain. However, it’s far from certain that we’ll see a quick share price recovery in 2020.

    While airlines are starting to ramp up their flight numbers, capacity is still well down on where we started the year. 

    There’s also another issue: demand. Just because there’s the ability to travel, many Aussies have fallen on hard times during the pandemic. 

    There could be a couple of ways this plays out for the Webjet share price. There could well be a surge in demand as people take advantage of the ability to travel.

    On the other hand, we could see more Aussies saving their cash and being conservative. There could also be some skepticism about travel safety despite more options being made available.

    All these unknowns say to me that the Webjet share price could be cheap but it’s a speculative play as to where the travel industry is headed.

    Foolish takeaway

    The Webjet share price surged higher last week and has some strong momentum behind it in this week’s trade.

    However, I feel the ASX travel share is far from a certain buy and I think I’ll wait until I see August earnings figures before jumping in.

    Here are a few more cheap ASX shares to buy in the month ahead.

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Webjet Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Is the Webjet share price a cheap buy today? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2XMW62N

  • G8 Education share price jumps higher despite the government ending its free childcare scheme

    child care shares

    The G8 Education Ltd (ASX: GEM) share price has been a strong performer this morning and is trading notably higher.

    At the time of writing the childcare centre operator’s shares are up over 6% to $1.10. This compares favourably to an impressive 3.1% gain by the S&P/ASX 200 Index (ASX: XJO).

    Why is the G8 Education share price outperforming?

    The catalyst for this outperformance has been an announcement this morning in response to one by the Federal Government on Monday.

    The latter announcement revealed that the government intends to end its free childcare scheme in July and reintroduce the Child Care Subsidy (CSS). It will also bring to an end its JobKeeper payment for workers in the sector next month.

    While you might imagine this to be a negative, it won’t actually be for G8 Education. This is because there will be a three-month transition period that aims to support the early learning sector during a period of reduced occupancy levels.

    According to G8’s announcement, early learning and care providers, including G8, will receive a transition payment equal to 25% of each centre’s fee levels prior to the impact of the pandemic. This is based on fees received in the fortnight prior to 1 March 2020.

    Management revealed that this equates to approximately half of the amount received under the relief package, but will be paid in addition to the normal CCS and co-parent payments. Though, this transition payment is conditional on early learning and care providers maintaining average gross employment levels during this period.

    Another positive is that the Federal Government will ease the activity test requirements that determine a family’s access to the CCS. Management expects this to make early learning more accessible and affordable to certain families. This includes those whose employment has been impacted due to the pandemic.

    G8 Chief Executive Officer and Managing Director, Gary Carroll, commented: “The transitional arrangements announced today are welcome as they provide operators with increased flexibility to support families as the economy recovers. We look forward to continuing to engage with government and other stakeholders to ensure the right settings are in place to support our families and team members.”

    What will be the financial impact?

    Management notes that the revised government support packages are structured in a way that means G8 expects to be in no worse a position relative to the prior support measures.

    This is even if occupancy levels become more subdued than they currently are.

    Occupancy levels update.

    The company also revealed that its booked occupancy rate is currently ~65%. However, physical attendance is approximately 52%, as some parents continue to choose to keep their children at home despite having a booking at a centre.

    During May, physical attendance improved ~20 percentage points off the April low of ~30%.

    Not sure about G8 right now? Then check out the highly recommended shares below…

    3 “Double Down” Stocks To Ride The Bull Market

    Motley Fool resident tech stock expert Dr. Anirban Mahanti has stumbled upon three under-the-radar stock picks he believes could be some of the greatest discoveries of his investing career.

    He’s so confident in their future prospects that he has issued “double down” buy alerts on each of these three stocks to members of his Motley Fool Extreme Opportunities stock picking service.

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post G8 Education share price jumps higher despite the government ending its free childcare scheme appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3h9JfiA

  • After Novavax Inks DoD Contract, Is Operation Warp Speed Ahead? Top Analyst Weighs In

    After Novavax Inks DoD Contract, Is Operation Warp Speed Ahead? Top Analyst Weighs InAnother day, another stride forward in the race to develop a COVID-19 vaccine.On June 4, Novavax (NVAX) revealed it will receive $60 million from the U.S. Department of Defense (DoD) to further the advancement of its experimental vaccine candidate, NVX-CoV2373, in the U.S., through JPEOCBRND-EB (Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies).As per the terms of the agreement, NVAX will work with multiple biologics contract development manufacturing organizations (CDMO) based in the U.S. to increase the scale of antigen and Matrix-M adjuvant production, which are both components of the vaccine. The end goal is to produce 10 million doses for the DoD in 2020, which will then be used in either a Phase 2/3 trial or under an Emergency Use Authorization (EUA).Weighing in on this development for B.Riley FBR, five-star analyst Mayank Mamtani tells investors he’s “encouraged” by the grant, arguing that the U.S. military is a “key population subset of national security importance.”However, Mamtani believes the implications go even further. “We believe this development is in sharp contrast to 3/6 media report speculating NVAX being excluded from the list of five finalists chosen by the Trump administration via Operation Warp Speed (OWS). In fact, this development further strengthens our conviction in a sizeable funding to be secured from U.S. BARDA which has ~$4 billion leftover from the original $6.5 billion allocation under the CARES Act for COVID-19 vaccine development and manufacturing; AstraZeneca/Univ. of Oxford, Moderna, J&J and Merck have been the beneficiaries to date, which might have been potential alternatives considered for this DoD contract,” he explained.While some investors might see the need for U.S.-based CDMO to deliver on this contract as a cause for concern, Mamtani points out that NVAX has already secured capacity. The $388 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) should be enough to support it through the Phase 2b trial. The non-dilutive funding will instead go towards the Phase 3 NVX-CoV2373 clinical efficacy (outcomes) study and large-scale manufacturing activities. The analyst added, “Here, we think U.S. BARDA could likely commit to secure access for '2373 to be expanded in high-risk, frontline workers and/or elderly in an effort to allow for approval of a tried and tested recombinant protein-based vaccine.”With earlier availability of the candidate for stockpiling now likely, the deal is sealed for Mamtani. The analyst rates NVAX a Buy along with a $74 price target. (To watch Mamtani’s track record, click here)      In general, other analysts echo Mamtani’s sentiment. 5 Buys and 1 Hold add up to a Strong Buy consensus rating. Given the $50.83 average price target, the upside potential comes in at 13.5%. (See Novavax stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/2XKBMiw

  • Is the Woolworths share price a buy?

  • Cloudflare Sees Uptick in Cyber Attacks as Internet Usage Increases

  • SpringWorks (SWTX): A Rare Cancer Biotech with Potentially >50% Upside. Recommending BUY.

  • Which markets or industries do you see perform best in the next decades (geographic vs. industry focus vs. cap size)? How do you build this into a strategy and portfolio to maximize expected risk-adjusted future returns?